Page 1840 - Hematology_ Basic Principles and Practice ( PDFDrive )

TABLE Comparison of Single-Unit Cord Blood Transplantation With Adult Donor Hematopoietic Stem Cell Transplantation
107.1
CI (%) of
Neutrophil
Engraftment
Age
Median Days to Neutrophil III–IV
Graft (range), in Conditioning Engraftment, II–IV Acute Acute
Reference (Patients n) years (Patients n) Median (range) GVHD GVHD Chronic GVHD NRM/TRM Relapse Survival
Eapen 503 CBT Unknown 25 (9–90) days
et al 26 35 matched (<1 to TBI 69% 85% at day +42 8/34 3/34 10/33 2/35 11/35 5-year LFS
<16) Non-TBI 31% 60%
1-Ag MM
157 high TBI 68% 80% at day +42 62/149 29/149 27/147 45/157 46/157 5-year LFS
dose Non-TBI 30% 45%
44 low dose TBI 82% 59% at day +42 16/44 9/44 7/39 19/44 9/44 5-year LFS
Non-TBI 14% 36%
2-Ag MM TBI 78% 76% at day +42 107/259 69/259 38/247 124/267 52/267 5-year LFS
267 Non-TBI 20% 33%
282 BM 19 (9–33) days
Matched 116 TBI 84% 97% at day +42 53/116 21/116 37/116 24/116 45/116 5-year LFS
Non-TBI 16% 38%
MM TBI 92% 97% at day +42 100/166 54/166 66/166 51/166 51/166 5-yr LFS
166 Non-TBI 8% 37%
Takahashi 100 CBT 38 TBI-based 91% at day +60 51% 6% Overall 73% 8% at day 17% at DFS 70% at
et al 25 (16–55) 22 (16-46) days Extensive 23% 100 3-years 3 years
9% at 1 year
71 RD 40 TBI-based 96% at day +60 36% 13% Overall 49% 4% at day 26% at DFS 60% at
55 BM/16 (16–58) 17 (10–35) days Extensive 30% 100 3 years 3 years
PBSC 13% at
1 year
Atsuta CBT 38 TBI-based 77% at day 32% – Overall 28% 30% at 27% at LFS
et al 31 173 AML (16–69) (89%) +100 Extensive 8% 1 year 1 year 43% at 1
Bu-Cy (10%) 33% at 31% at year
2 years 2 years 36% at 2
years
UD-BMT 38 TBI-based 94% at day 35% – Overall 32% 19% at 20% at LFS
311 AML (16–60) (82%) +100 Extensive 20% 1 year 1 year 62% at 1
Bu-Cy (18%) 22% at 24% at year
2 years 2 years 54% at 2
years
CBT 34 TBI-based 80% at day 28% – Overall 27% 21% at 27% at LFS
114 ALL (16–58) (97%) +100 Extensive 10% 1 year 1 year 52% at 1
Bu-Cy (3%) 24% at 19% at year
2 years 2 years 45% at 2
years
UD-BMT 32 TBI-based 97% at day 42% – Overall 30% 23% at 31% at LFS
222 ALL (16–59) (91%) +100 Extensive 17% 1 year 1 year 58% at 1
Bu-Cy (5%) 25% at 24% at year
2 years 2 years 51% at 2
years
Eapen 165 CB 28 (16 to TBI (55%) 24 (12–68) days 49/162 – 39/161 37% at 43/165 LFS 98/165
et 22 >50) ATG (72%) 80% at day +42 2 years at 2 years
888 URD 33 (16 to TBI (66%) 14 (5–28) days –
PBSC >50) ATG (18%) 96% at day +42
632 matched 303/630 – 327/632 24% at 209/632 LFS
2 years 358/632
at 2 years
265 1-Ag 134/256 – 113/256 38% at 77/256 LFS
MM 2 years 170/256
at 2 years
472 URD BM 39 (16 to TBI (68%) 19 (6–41) days –
>50) ATG (28%) 93% at day +42
332 matched 129/332 – 132/332 22% at 112/332 LFS
2 years 188/332
at 2 years
140 1-Ag 64/139 – 51/140 34% at 2 42/140 DFS 80/140
MM years
Ag, Antigen; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; CBT, cord blood transplantation; DFS, disease-free survival;
GVHD, graft-versus-host disease; LFS, leukemia-free survival; MM, mismatched; NRM, nonrelapse mortality; PBSC, peripheral blood stem cell; RD, related donor;
TBI, total-body irradiation; TRM, transplant-related mortality; URD, unrelated donor.